Form D · Biotechnology
HEMOSHEAR THERAPEUTICS, INC.
Charlottesville, VA · CIK 0001846099
Offering snapshot reported Nov 14, 2023 · SEC filing
- Reported sold
- $3.5M Offering amount: $8M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 14, 2023 | Initial | $3,500,000 | No comparison | 4 | SEC filing |
| Feb 18, 2021 | Initial | $43,102,017 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-497215
Source: Form D, filed Nov 14, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John L. Brooks | Director |
| John L Brooks Iii | Director |
| David Friedman | Director |
| Robert J Gould | Director |
| Aric Holsinger | Executive |
| Patrick Horn | Executive |
| Michael Innes | Executive |
| Brian A Johns | Executive |
| Kathleen M Metters | Director |
| James C. Powers | Director, Executive |
| W. M. Thompson, Jr. | Executive |
| John Tilton | Director |
| Brian Wamhoff | Executive |
| Brian Warmhoff | Director, Executive |
| H. Thomas Watkins Iii | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
501 Locust Avenue, Suite 301
Charlottesville, VA, 22902
Charlottesville, VA, 22902